Effect Of Emicizumab In Patients With Hemophilia A Without Inhibitors

Synopsis Clinical evidence suggests that Emicizumab prophylaxis administered subcutaneously, led to a significantly lower bleeding rate in the patient with hemophilia A without inhibitors. The present study aims to assess the efficacy, safety and pharmacokinetics of Emicizumab prophylaxis in persons who have hemophilia A without inhibitors. This week’s “ MED FACT ” discusses a clinical study from The New England Journal of Medicine, “ Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors ”.30 Aug 2018. Authors : J. Mahlangu; J.

Oldenburg; I. Paz ‑Priel; et. al. Key Takeaways:   Once weekly or every 2 weeks subcutaneous Emicizumab prophylaxis significantly results in lowering bleeding rate by more than 95% as compared to the rate with no prophylaxis. Objective: To assess the efficacy, safety and pharmacokinetics of Emicizumab prophylaxis in patients with hemophilia…